Stroke Trial, Recruiting (NCT04230785)

Stroke Trial, Recruiting NCT04230785 Sponsor: Nanjing First Hospital, Nanjing Medical University Condition: Stroke

Printed from Voxsanity (voxsanity.com.au) — NCT04230785 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Stroke

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 years or older.
People who have been confirmed to have an acute (sudden-onset) ischemic stroke, shown by specific brain scans — an MRI and a CT scan — that identify a new area of damage in the brain.
People who are within 24 hours of when their stroke symptoms began and are being treated with a procedure to unblock blood vessels in the brain (endovascular therapy).
People who are in generally good physical condition before the stroke (confirm with trial site for exact definition).
People who have signed an approved consent form agreeing to take part in the trial.

Who may not be able to join:

People with a history of any of the following: a stroke that involved bleeding into the brain (hemorrhagic infarction), long-term kidney disease, long-term liver disease, blocked arteries in the limbs (peripheral arterial occlusive disease), an active cancer diagnosis, or an ongoing inflammatory or infectious disease.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Junshan Zhou, M.D, Nanjing First Hospital, Nanjing Medical University

Phone: +8602587726218

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04230785

Sponsor: Nanjing First Hospital, Nanjing Medical University

Phase: Not Applicable

Status: Recruiting

Condition: Stroke

Trial contact: +8602587726218

More information: https://clinicaltrials.gov/study/NCT04230785

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 years or older.
People who have been confirmed to have an acute (sudden-onset) ischemic stroke, shown by specific brain scans — an MRI and a CT scan — that identify a new area of damage in the brain.
People who are within 24 hours of when their stroke symptoms began and are being treated with a procedure to unblock blood vessels in the brain (endovascular therapy).
People who are in generally good physical condition before the stroke (confirm with trial site for exact definition).
People who have signed an approved consent form agreeing to take part in the trial.

Who may not be able to join:

People with a history of any of the following: a stroke that involved bleeding into the brain (hemorrhagic infarction), long-term kidney disease, long-term liver disease, blocked arteries in the limbs (peripheral arterial occlusive disease), an active cancer diagnosis, or an ongoing inflammatory or infectious disease.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Nanjing First Hospital, Nanjing Medical University

Registry

ClinicalTrials.gov

Start date

15 March 2020

Est. completion

1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Differential expression pattern of circRNA/lncRNA/miRNA in acute ischemic stroke patients before and after endovascular treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov